Liquid Crystal Pharmaceuticals (LCP™) are an exciting new area for drug development. In the 1970’s early liquid crystal research supported few biological applications. This work was primarily aimed at developing better LCD technologies responsible for today’s $60 billion flat screen industry. More recently however, liquid crystal researchers have turned their interests to intricate biological applications useful in medicine. Together with modern bioinformatics techniques, this has led to the discovery of liquid crystals as drug that more safely target and kill cancerous and other aberrant cells.
The properties of biologically active liquid crystals are complex. However useful mechanisms of action include cell signal inhibition, control of intracellular ROS, gene delivery and regulation of transcription factors responsible for whole banks of genes necessary for regulatory processes. Consequently, LCP’s offer less toxic, more effective new drugs for the treatment of cancer and other diseases.
IC-MedTech, Inc. is a privately held San Diego biopharmaceutical company engaged in early to mid-stage LCP drug development. The company utilizes commercial drug discovery techniques based on computational and laboratory screening for biologically relevant mesogens. At the nano-scale the unique properties of liquid crystals are known to “switch on” physical, chemical and electronic mechanisms useful for the treatment of disease. The company owns exclusive rights to a family of pre-clinical compounds useful for the treatment of viral and bacterial infections, as well as clinical stage anti-neoplastics for treatment of a wide range of human cancers.
IC-MedTech creates value by in-licensing related technologies, investing in intellectual property development and the creation of appropriate regulatory and business strategies. The company’s product pipeline includes a wide range of patented LCP’s and their applications. Examples include Apatone®, Tolecine™, Anniahlase™, KST 301 and 401 and other technologies useful for improved drug safety and efficacy. |
